Research & Development

How Will eXmoor's New License Transform Cell and Gene Therapy?
Research & Development How Will eXmoor's New License Transform Cell and Gene Therapy?

The transformative journey of eXmoor Pharma has reached a pivotal moment with the recent acquisition of a Manufacturing and Import Authorization for Investigational Medicinal Products (MIA(IMP)) license from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). This milestone

Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?
Research & Development Will BNT326/YL202 Overcome Safety Issues to Become a Cancer Therapy?

The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and

Lawmakers Urge FDA to Probe U.S.-China Military-Linked Clinical Trials
Research & Development Lawmakers Urge FDA to Probe U.S.-China Military-Linked Clinical Trials

Recent tensions between the United States and China have extended into the biotech and pharmaceutical sectors, sparking bipartisan calls for increased regulatory scrutiny. At the heart of the matter: clinical trials conducted by U.S. pharmaceutical companies in collaboration with Chinese

Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk and Weight Loss
Research & Development Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk and Weight Loss

Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and

FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial
Research & Development FDA Lifts Hold on BioNTech and MediLink’s Cancer Drug Trial

In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,

FDA Approves Tanvex's NYPOZI and Accepts BLA for Cancer Treatment
Research & Development FDA Approves Tanvex's NYPOZI and Accepts BLA for Cancer Treatment

In a significant breakthrough for cancer treatment options, Tanvex BioPharma USA, Inc. ("Tanvex" or the "Company") announced that the FDA has approved their biosimilar product NYPOZI (filgrastim-txid) and accepted their Biologics License Application (BLA) for TX-05. These

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later